Investigating how MHC-E presents diverse antigens for AIDS vaccine development
Non-canonical epitope presentation and antigen processing by MHC-E
['FUNDING_R01'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-10935982
This study is looking at how a special molecule helps the immune system recognize different pieces of viruses, with the goal of creating a better vaccine for AIDS, and it could lead to new ways to boost the body's defenses against HIV.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-10935982 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a specific molecule, MHC-E, presents a variety of antigens to the immune system, particularly in the context of developing a vaccine for AIDS. The study utilizes a modified cytomegalovirus (CMV) to elicit immune responses that can control and potentially clear the simian immunodeficiency virus (SIV). By examining the mechanisms behind MHC-E's ability to present non-canonical peptides, the research aims to uncover new strategies for enhancing T cell immunity against HIV. Patients may benefit from insights gained that could lead to more effective vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for HIV infection or those living with HIV who may benefit from improved vaccine strategies.
Not a fit: Patients who are not at risk for HIV or those who have already achieved viral suppression with current therapies may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective AIDS vaccine that enhances immune responses against HIV.
How similar studies have performed: Other research has shown promise in using unconventional approaches to vaccine development, but this specific focus on MHC-E is relatively novel.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FRUH, KLAUS J — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: FRUH, KLAUS J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus